Clinical tumour society's conference of U.S.A. : Many kinds of new medicine appearance of accusing of the anticancer of tumour

Clinical tumour society's conference of U.S.A. : Many kinds of new medicine appearance of accusing of the anticancer of tumour
Learn the conference to hold in Chicago of U.S.A. in U.S.A. clinical tumour. At the meeting on the 5th, many pharmaceutical manufacturers and research institution release the new medicine, propose the new view in treating cancer, some medicines obtain the clinical favorable comment, some treatments cure the cancer direction as the future.
Delay shifting
American Amgen the intersection of monoclonal antibody and new the intersection of medicine and promise Di researched and developed newly to put out fill wheat (Denosumab) in at conference . The clinical trial verifies, this kind of medicine can be delayed in later period effectively the bone takes place for time to shift to the cancer patient of prostate.
The present stage, prevent or delay patient, cancer of prostate, take place medicine that bone shift rely on the intersection of Swiss and the intersection of Novartis and that Company produce two the intersection of phosphoric acid and saline the intersection of medicine and thiazole come phosphoric acid (Zometa) mainly . In to 1900 the intersection of contrast and test that patient launch, compare thiazole, come phosphoric acid, promise Di fill in wheat can take place patient time that bone shift delay 3.6 months on average.
Meanwhile, promise Di fill wheat in, verify by clinical trial, can contain growth, bone marrow of cancer effectively.
In prostate cancer is developed until later period, will generally present the bone of cancer cell and shift the situation, exceeding 80's later period, the patient has bone to shift the phenomenon, the common bone shifts the focus and can be seen in places such as projecting cheek bone, body of vertebra, rib, skull,etc..
At the meeting, Amgen point out not only to the intersection of prostate and cancer, promise Di fill wheat in can bone marrow cancer and other entity tumours same utility produces to breast cancer, person who occur frequently also.
In U.S.A., promise Di fill in the wheat and get approval of Food and Drug Administration last week, with general Rolya (Prolia) The name of parenteral solution goes on the market, but only stipulate at the present stage that is used for treating hopeless menstrual woman's osteoporosis.
Stimulate the immunity
American Bristol-Myers Squibb Co. introduces a at the meeting and is still at new medicine which tests stage, call very effective the intersection of extension and the intersection of skin carcinoma and life of patient, until mortality supreme melanotic cancer especially effective in the skin carcinoma.
Melanotic cancer belongs to malignant cancer, come from the black plain cell canceration of the skin, mucous membrane, eyes and pigmented area of central nervous system, it is the past 30 In the period of plant by cancer. At stage now, there is no effective treatment directed against melanotic cancer yet in the whole world, about 6000 people die of melanotic cancer in the whole year in U.S.A., increase the case newly every year 2.5 Ten thousand .
Via the intravenous injection, the apt general favourable nurse agate (Ipilimumab) of monoclonal antibody medicine which Bristol-Myers Squibb Co. puts out Lengthen the life of the melanotic cancer patient of later period greatly, among them the life of patient of 24 lengthens over 2 years.
|